Clinical trials
Terminated Cystic Fibrosis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 3 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 4 |
| 2021 | 4 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 56 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Vertex Pharmaceuticals Incorporated | 5 |
| University of North Carolina, Chapel Hill | 3 |
| Boehringer Ingelheim | 2 |
| Dartmouth-Hitchcock Medical Center | 2 |
| Gilead Sciences | 2 |
| Novartis Pharmaceuticals | 2 |
| PTC Therapeutics | 2 |
| Stanford University | 2 |
| University of Colorado, Denver | 2 |
| University of Massachusetts, Worcester | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cystic Fibrosis | 56 |
| Pulmonary Disease, Chronic Obstructive | 4 |
| Lung Diseases | 3 |
| Bronchiectasis | 2 |
| Diabetes Mellitus | 2 |
| Exocrine Pancreatic Insufficiency | 2 |
| Genetic Diseases, Inborn | 2 |
| Inflammation | 2 |
| Respiratory Tract Diseases | 2 |
| Aspergillosis, Allergic Bronchopulmonary | 1 |
Trials
Showing 1 to 25 of 56. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.